Stockscreener 앱 받기
2.74
0.36%
-0.010
Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스
Medicus Pharma completes $7 million public offering By Investing.com - Investing.com South Africa
Medicus Pharma completes $7 million public offering - Investing.com
Medicus Pharma Secures $7 Million for Cancer Treatment Trials - TipRanks
Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering - Newsfile
Medicus Pharma closes $7M public offering - Proactive financial news
Medicus Pharma prices $7 million share offering - MSN
Health Sector Experiences Mixed Fortunes As Trials And Stock Moves Shake Up Market - Finimize
Biotech Stocks Plummet As Public Offerings Shake Market - Finimize
Sector Update: Health Care - marketscreener.com
Form 424B4 Medicus Pharma Ltd. - StreetInsider
Small cap wrap: ReconAfrica, Charbone Hydrogen, Medicus Pharma.... - Proactive financial news
Medicus Pharma Prices $7 Million Public Offering; Shares Fall - marketscreener.com
Medicus Pharma unveils pricing of $7M public offering - Proactive financial news
Medicus Pharma’s (MDCX) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Medicus Pharma (NASDAQ:MDCX) Upgraded at Wall Street Zen - Defense World
Medicus Pharma Ltd. Launches $7 Million Public Offering to Advance Cancer Treatment Trials - TipRanks
Medicus Pharma Secures $7M Funding to Advance Revolutionary Skin Cancer Patch Through Phase 2 Trials - Stock Titan
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering - Newsfile
Medicus Pharma Files For Resale From Time To Time Of Up To 3.7 Mln Common Shares - marketscreener.com
Medicus Pharma begins UAE cancer trial expansion – ICYMI - Proactive financial news
Medicus Pharma’s (MDCX) Buy Rating Reiterated at D. Boral Capital - Defense World
OpenAI’s $6.5B Deal With Jony Ive Hints at a Post-iPhone AI Era - The Globe and Mail
Medicus Pharma receives UAE approval to begin Phase 2 study for non-invasive BCC treatment - Proactive financial news
Small cap wrap: Nextech3D.ai, Medicus Pharma, Synchronoss, ReconAfrica... - Proactive financial news
Medicus Pharma Ltd. Gains UAE Approval for Phase 2 Basal Cell Carcinoma Study - TipRanks
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates Department of Health to Commence Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin - Malay Mail
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) - Newsfile
New Non-Invasive Skin Cancer Treatment Advances to Phase 2 in UAE After 46% Success Rate - Stock Titan
Medicus Pharma gets UAE approval for Phase 2 study for skin cancer therapy - Proactive financial news
Major Shareholder Sells Off Huge Chunk of Medicus Pharma Stock! - TipRanks
This Magnificent Stock Is Up 370% From Its 2022 Low -- 2 Reasons to Buy It Now, and 1 Reason to Steer Clear - The Globe and Mail
Chart of the DayJuly Wheat - The Globe and Mail
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money - The Globe and Mail
Is Google Stock Worth Buying In 2025? - The Globe and Mail
Medicus Pharma (NASDAQ:MDCX) Price Target Raised to $27.00 at D. Boral Capital - Defense World
Pre-market Movers: CNSP, XLO, PLRZ, SGMO... - RTTNews
Medicus Pharma Ltd. SEC 10-Q Report - TradingView
Medicus Pharma price target raised to $27 from $14 at D. Boral Capital - TipRanks
Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio - Benzinga
Medicus Pharma secures $15 million funding option - MSN
Medicus Pharma stock target lifted to $27 on Antev acquisition By Investing.com - Investing.com Nigeria
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Medicus Pharma stock target lifted to $27 on Antev acquisition - Investing.com Australia
Certain Common Shares of Medicus Pharma Ltd. are subject to a Lock-Up Agreement Ending on 12-MAY-2025. - marketscreener.com
Certain Options of Medicus Pharma Ltd. are subject to a Lock-Up Agreement Ending on 12-MAY-2025. - marketscreener.com
Maxim Group Upgrades Medicus Pharma (CVE:MDC) to “Strong-Buy” - Defense World
Medicus Pharma to acquire Antev, advancing opportunity in prostate health solutions - Proactive financial news
Medicus Pharma to acquire Antev for $75M in share exchange transaction - MSN
Medicus Pharma signs letter of intent to buy British biotech company - The Business Journals
3 Reasons to Avoid HLIO and 1 Stock to Buy Instead - The Globe and Mail
0.39%
0.28%
자본화:
|
볼륨(24시간):